Equities

Stem Cells Spin SA

SCS:WSE

Stem Cells Spin SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)0.258
  • Today's Change0.00 / 0.00%
  • Shares traded50.00
  • 1 Year change-37.07%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stem Cells Spin SA is a Poland-based company. It is primarily engaged in biotechnology research. The Company is focused on development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets.

  • Revenue in PLN (TTM)223.67k
  • Net income in PLN-353.29k
  • Incorporated2011
  • Employees1.00
  • Location
    Stem Cells Spin SAWroclawski Park Technologiczny S.A.Budynek BETA, ul. Klecinska 125WROCLAW 54-413PolandPOL
  • Phone+48 713265403
  • Fax+48 717359347
  • Websitehttp://stemcellsspin.com.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Private Rented Sector SA100.00k-67.14k4.02m----75.07--40.17-0.0508-0.05080.07570.04050.3935--0.4425---26.421,286.86-76.74---51.98-1,929.58-67.142,759.04---1,111.500.00-------57.33------
Sygnis SA12.42m-5.52m10.60m34.00--0.2946--0.8537-0.2396-0.23960.53141.430.17520.619415.06326,799.50-7.89-5.73-14.77-8.3160.8256.42-45.06-21.110.4425-0.74120.1151---33.3844.26-241.23--39.45--
Stem Cells Spin SA223.67k-353.29k10.66m1.00--1.4914.1647.68-0.0086-0.00860.00540.17340.01630.07394.38223,670.00-2.58-1.14-4.18-1.9380.2494.37-157.95-45.360.0118-225.540.0074--68.84-4.37-680.05---52.67--
Braster SA284.00k-4.30m18.03m10.00------63.47-0.1494-0.14940.0098-0.17170.01350.00382.7028,400.00-20.43-29.93-147.09-72.5493.6679.59-1,513.38-1,124.890.2905-2.661.77---88.96-18.1128.68------
Hyenergy SA462.00k-6.12m23.25m27.00--8.27--50.33-1.06-1.060.07760.45350.06250.97371.39---82.831.90-115.272.58-44.1676.43-1,325.332.661.20-1.000.0106---93.14-16.73-2,069.21------
Medicofarma Biotech SA1.37m-2.73m26.17m----3.01--19.12-0.0402-0.04020.02010.1280.08954.574.74---17.87-15.05-23.82-18.1781.9229.92-199.65-42.860.8394-18.900.00---82.34-31.48-116.39------
GENOMED SA22.14m588.66k34.62m44.0058.813.7328.991.560.44550.445516.757.022.175.8514.12503,111.405.777.776.399.1944.0038.532.663.874.6430,446.000.00--9.883.88174.07-8.94-32.19--
Data as of Nov 12 2024. Currency figures normalised to Stem Cells Spin SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.